An interventional study of Medication intake reminders and Pillbox use and counselling in Adherence, Patient and Stroke, Ischemic, sponsored by University Hospital, Basel, Switzerland. Completed at 1 site in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-12-21.
Sponsored by University Hospital, Basel, Switzerland · Not applicable, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies in Patient Compliance with a site in Switzerland — 3 open to participants now, 3 under way, none of them phase 3. Patient Compliance · Switzerland.
Among the 19 studies in Patient Compliance with a site in Switzerland, this one is the 6th largest by enrollment of the 14 interventional ones that give a count, is one of 2 that started in 2017, is one of 10 with no phase, and was the 13th registered.
752 studies on the registry are indexed under Patient Compliance; 72 are open to participants now.
Browse Patient Compliance studies →3 of the 19 studies in Patient Compliance with a site in Switzerland are open now. Recruiting first, the newest first:
Liliana Barrios · Sites in Switzerland
Ages 18–65 · Healthy volunteers
University of St.Gallen · Sites in Switzerland
Ages 45+ · Healthy volunteers
University of Geneva, Switzerland · Sites in Switzerland
Ages 18+
A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →
Of the 45 Patient Compliance studies recruiting now, 25 (56%) set no upper age limit and 13 (29%) stop at 75 or younger; 11 take children under 18; 14 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 2 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 130 is above the median of 116 across 527 interventional studies indexed under Patient Compliance.
Median enrollment 110 across the 14 interventional studies, 55 across the 5 observational. Of the 14 that completed or were terminated, 1 (7%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 19 have an industry lead sponsor. The 10 most frequent:
University Hospital, Basel, Switzerland is the lead sponsor of 990 studies on the registry; 189 are open to participants now.
University Hospital, Basel, Switzerland has 2 studies filed under Patient Compliance — fewer than ten, so there is no comparison to draw.
2 of the studies in Patient Compliance with a site in Switzerland that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07036471University of Geneva, SwitzerlandSupporting Patients Starting New Medicines: Evaluating the myCare Start Service in Switzerland | 2027-01 |
| NCT07555262University of St.GallenReminder Strategies to Improve Meal-Logging Adherence | 2027-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 19 studies in Patient Compliance with a site in Switzerland, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Primary objective of the MAAESTRO trial is to evaluate the impact of an educational and reminder-based intervention on the adherence of stroke patients to DOACs. Secondary objectives are to evaluate the association between non-adherence and clinical events, to identify predictors of non-adherence and to compare objective measures of adherence with self-reporting.
Key methodological instrument for this study will be the "Time4Med" pillbox with Smart/ Reminder Card. The study includes 3 visits (baseline visit 0, follow-up visit 1 and end-of-study visit 2) with a total follow-up of 9 months.
After an initial 3-month observational phase with electronic monitoring of adherence using the "Smart Card", all patients will receive counselling based on their electronically recorded drug intake data, as well as a multicompartment pillbox. Patients will be then randomised to one of two groups in a crossover design, so that in the subsequent 6-month interventional phase one group will use a (reminder-delivering) "Reminder Card" for the first 3 months and the "Smart Card" for the last 3 months, while the second group will use the cards in reverse order.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Intake reminders followed by crossover to no intake reminders
Behavioral: Medication intake reminders · Behavioral: Pillbox use and counselling
No intake reminders followed by crossover to intake reminders
Behavioral: Medication intake reminders · Behavioral: Pillbox use and counselling
Acoustic and visual alarm at predefined DOAC-intake timepoints.
All patients will be counselled based on their previous electronically recorded adherence data and will be given a multicompartment pillbox für daily use
Change of non-optimal timing adherence to DOACs
Non-optimal timing adherence is defined as at least one DOAC dose not recorded or recorded outside of 25% of the prescribed dosing time schedule
Time frame: 0 - 3 months, 3 - 6 months, 6 - 9 months
Change of non-optimal taking adherence to DOACs
Non-optimal taking adherence to DOACs is defined as at least one DOAC dose not recorded
Time frame: 0 - 3 months, 3 - 6 months, 6 - 9 months
Change of timing adherence to DOACs
Timing adherence to DOACs is defined as the proportion of prescribed DOAC doses taken within 25% of the prescribed dosing time schedule
Time frame: 0 - 3 months, 3 - 6 months, 6 - 9 months
Change of taking adherence to DOACs
Taking adherence to DOACs is defined as the proportion of prescribed DOAC doses taken.
Time frame: 0 - 3 months, 3 - 6 months, 6 - 9 months
Self-reported adherence to DOACs
Self-reported adherence to DOACs is captured on various questionnaires
Time frame: 0 - 6 months
Clinical vascular events or death
Recurrent ischaemic stroke or TIA, intracranial hemorrhage, major extracranial hemorrhage, myocardial infarction, venous thromboembolism and death
Time frame: up to 9 months
Plan to share: No
Ran from Dec 2017 to primary completion in Mar 2022, 51 months.
Of 224 non-industry interventional studies with no phase under Patient Compliance, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 38. This study's 51 months is above that.
Counting every sponsor, half of 237 studies reached it within 20 months; a quarter within 9 and three quarters within 38.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Basel, Switzerland →